TL1A-Binding Antibodies Block DR3 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively block the interaction between DR3 and TL1A, which contributes to inflammatory and autoimmune diseases by enhancing T cell activation and cytokine production, leading to conditions like asthma, multiple sclerosis, and inflammatory bowel disease.
Innovation Solution
Blocking the interaction between DR3 and TL1A using agents that reduce their levels or activity, such as functional nucleic acids, dominant negative mutants, DR3 Fc fusion proteins, or antibodies that specifically bind to TL1A or DR3, thereby inhibiting their signaling pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If the interaction between DR3 and TL1A is blocked using antibodies or other agents, then T cell activation and cytokine production are reduced, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent employs antibodies as intermediary molecules that specifically bind to either DR3 or TL1A, preventing their direct interaction. These antibody intermediaries block the harmful signaling pathway while maintaining a relatively simple administration protocol, thus resolving the contradiction between effectiveness and complexity
Solution Approach 2:
The invention extracts and isolates the specific DR3-TL1A interaction pathway from the complex immune system, targeting only this specific pathogenic mechanism. By using highly specific antibodies that only bind to DR3 or TL1A, the treatment selectively blocks the harmful interaction without disrupting other immune functions, simplifying the treatment approach while maintaining efficacy
2Reliability
If functional nucleic acids or dominant negative mutants are used to block DR3-TL1A interaction, then the therapeutic effect is enhanced, but the manufacturing precision requirements increase
Solution Approach 1:
The patent uses antibodies as simplified copies or proxies for the complex functional nucleic acids and dominant negative mutants. These antibodies achieve the same therapeutic effect of blocking DR3-TL1A interaction but with significantly reduced manufacturing complexity and higher precision control, as antibody production through hybridoma technology or recombinant methods is more standardized and controllable
Solution Approach 2:
The invention changes the molecular parameter from complex functional nucleic acids or dominant negative mutants to antibodies, which have well-defined structural and functional parameters. This parameter change enables more precise control over binding affinity, specificity, and pharmacokinetic properties, thereby improving manufacturing precision while maintaining therapeutic reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces T cell activation and cytokine production, effectively ameliorating inflammatory and autoimmune diseases by inhibiting the TL1A/DR3 interaction, as demonstrated in animal models of asthma, multiple sclerosis, and inflammatory bowel disease.
Implementation Method 1
Antibodies that specifically bind to TL1A or DR3, thereby inhibiting their signaling pathway
Data Source
AI summary
Provided are methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD).